Pathological angiogenesis is a hallmark of multiple chronic diseases and cancer. Antiangiogenic therapies have the potential to prevent vision loss, such as in wet AMD or diabetic retinopathy and to promote cancer regression. While anti-VEGF therapies have shown outstanding clinical success in some cases, we still need better, more powerful and more sustained angiogenesis blockade therapies.

We developed an in vitro system that is suitable for the long-term analysis of 3D lumenized vessels and we are using it to assay novel agents to induce vessel regression. Using multiwell plates and automated image analysis, we can follow changes in real time for multiple weeks.